Figure 1. Scopes 1, 2, and 3 for greenhouse gas emission analysis.
Regarding environmental assessment, “Scope” refers to the emissions categories specified in the greenhouse gas (GHG) Protocol. Scope 1: Direct GHG emissions by the business itself. Scope 2: Indirect GHG emissions from the use of electricity, heat, and steam supplied by other companies. Scope 3: All indirect emissions other than Scopes 1 and 2. Scope 3 is defined as GHG emissions from all business activities, including suppliers, excluding Scopes 1 and 2. The author prepared this figure based on information published by the Ministry of the Environment, Government of Japan on its website (https://www.env.go.jp/earth/ondanka/supply_chain/gvc/estimate.html).
From: Movement toward Environmentally Friendly Pharmaceuticals in Japan
Figure 2. Proportion of Scopes 1, 2, and 3 in large drug companies in Japan.
Among the top 12 Japanese pharmaceutical companies (by sales) having annual sales of ≥300 billion yen in 2021, the mean proportions of Scopes 1, 2, and 3 were calculated. The author prepared this figure based on the background information freely available on each company’s website for the public or investors.
From: Movement toward Environmentally Friendly Pharmaceuticals in Japan
Figure 3. Greenhouse gas emission reduction targets stated by drug companies in Japan.
The upper row shows the overall emission reduction targets stated by the Japanese government and actual emissions by 2019 in Japan. Emissions data were taken from the National Institute for Environmental Studies (https://www.nies.go.jp/gio/archive/ghgdata/index.html). The top 12 Japanese pharmaceutical companies stated their greenhouse gas reduction targets in Scopes 1 + 2, and this information is freely accessible on each company’s website for the public or investors. *Greenhouse gas emissions for all of Japan. Units are million ton CO2-eq. **Sales > 300 billion yen. Abbreviations: B, baseline year; CN, carbon neutral; GHGE, greenhouse gas emission.
From: Movement toward Environmentally Friendly Pharmaceuticals in Japan
